title: Interplay between cancer cells, macrophages and natural killer cells may actually decide the outcome of therapy with sorafenib.
authors: Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania; Department of Hematology, Ion Chiricuta Comprehensive Cancer Center, Cluj Napoca, Romania.
authors: Ciprian
authors: C
authors: Tomuleasa
authors: Gianluigi
authors: G
authors: Giannelli
authors: Andrei
authors: A
authors: Cucuianu
authors: Mihaela
authors: M
authors: Aldea
authors: Angelo
authors: A
authors: Paradiso
authors: Ioana
authors: I
authors: Berindan-Neagoe
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008262:Macrophage Activation / Q000187:drug effects*; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide